Jpmorgan Chase & CO Rapt Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 16,703 shares of RAPT stock, worth $27,058. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,703
Previous 16,573
0.78%
Holding current value
$27,058
Previous $50,000
34.0%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding RAPT
# of Institutions
104Shares Held
27.1MCall Options Held
26.7KPut Options Held
2.4K-
Vanguard Group Inc Valley Forge, PA3.16MShares$5.11 Million0.0% of portfolio
-
Column Group LLC San Francisco, CA2.68MShares$4.34 Million7.75% of portfolio
-
Black Rock Inc. New York, NY2.44MShares$3.95 Million0.0% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY1.73MShares$2.79 Million0.42% of portfolio
-
Ponoi Management, LLC San Francisco, CA1.6MShares$2.59 Million52.54% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $48M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...